BiotechTube
Home/Pipeline/BP1003

BP1003

Not Specified

PreclinicalActive

Key Facts

Indication
Not Specified
Phase
Preclinical
Status
Active
Company
Bio-Path Holdings

About Bio-Path Holdings

Bio-Path Holdings is an oncology-focused biotech developing non-toxic, targeted cancer therapies for fragile patients ineligible for standard chemotherapy. Its core innovation is the DNAbilize® liposomal delivery platform, designed to concentrate antisense drugs at the tumor site while sparing healthy tissue. The company's strategy centers on advancing its lead asset, prexigebersen, in AML while exploring its platform's utility in solid tumors and other blood cancers through earlier-stage candidates. Recent leadership changes aim to revitalize clinical progress and corporate strategy.

View full company profile

Therapeutic Areas

OncologyHematologic CancerSolid Tumors

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved